선택적 제품 분석
허용하는 경우 개인정보 보호를 고려한 제한적 분석을 사용해 어떤 리서치 여정이 효과적인지 파악합니다. 광고 추적기나 세션 녹화는 사용하지 않습니다. 환경설정에서 이 선택을 변경할 수 있습니다. 자세한 내용은 개인정보 처리방침.
The primary upside opportunity lies in Altria's commercial expansion of on!
Domestic cigarette shipment volume contraction accelerates beyond 8.0% year-over-year, driven by potential FDA regulatory actions such as product standards banning menthol in cigarettes or consumer price elasticity breaking after repeated ~7% annual Marlboro price hikes.
Altria Group Inc. (MO) is maintained at a Reduce rating as current trading levels ($75.11 as of October 16, 2026) reflect a 21.9% price premium over mid intrinsic fair value of $61.61, leaving investors with an implied return of -18.0%. While Marlboro pricing power continues to sustain near-term cash generation, secular combustible cigarette volume contraction (-4.5% trade-adjusted in Q2 2026), consumer trade-down into discount brands (33.8% category share), and execution roadblocks in modern smoke-free platforms create an unfavorable risk/reward profile.34
Altria Group Inc. presents a fundamental conflict between world-class cash extraction in a declining legacy business and structural vulnerability in future nicotine categories. Operating income in FY2025 reached $9,899M on net of $23,279M, generating $9,074M in after just $216M in . This cash engine is driven almost entirely by Philip Morris USA, whose flagship Marlboro brand commands 59.6% of the U.S. premium cigarette segment. By raising Marlboro retail prices ~7% annually against an inelastic demand coefficient of -0.35, management expanded Smokeable adjusted OCI margins to 64.9% in H1 2026, supporting $3.9B in dividends and buybacks across the first six months of 2026.
However, this pricing umbrella is encountering structural stress. In Q2 2026, reported domestic cigarette shipment volume declined 3.2% (4.5% adjusted for trade inventories), with Marlboro volume contracting 7.4%. Persistent macroeconomic inflation has pressured lower-income adult consumers to trade down, driving discount cigarette category share up 2.6 percentage points to 33.8%. While PM USA has expanded Marlboro Cowboy Cut and Basic to capture value-sensitive smokers, product mix is progressively diluting net revenue realization. Furthermore, the company relies heavily on two wholesale distributors who account for 42% of consolidated net revenues.4
Altria's strategic transition toward smoke-free platforms has not scaled rapidly enough to offset the combustible decline. While Helix has expanded on! PLUS to 120,000 stores, on! captured only 14.4% of the nicotine pouch category in Q2 2026, down 1.7 percentage points year-over-year. In e-vapor, NJOY ACE remains barred from importation in 2026 under ITC exclusion orders, leaving Altria without a commercial presence in modern vapor following an $873M goodwill impairment in 2025. Meanwhile, illicit disposable vapes continue to siphon adult nicotine consumers away from authorized retail channels.4
At $75.11 (as of 2026-10-16), Altria shares trade above Fair value ($61.61), offering -18.0% implied upside toward the midpoint. With negative stockholders' equity and substantial total debt, the valuation provides little margin of safety against regulatory shocks or continued trade-down into discount cigarette categories.
Marlboro maintained a 59.6% share of the U.S. premium cigarette segment and 39.5% total cigarette category retail share in Q2 2026. This pricing power enabled Philip Morris USA to lift Marlboro retail prices by ~7% YoY in Q2 2026 while maintaining a stable -0.35 price elasticity coefficient, expanding Smokeable segment adjusted OCI margins to 64.8% in Q2 2026 and 64.9% in H1 2026.4
Altria operates an entrenched nationwide distribution network reaching over 120,000 retail locations for on! PLUS, supported by long-term Master Settlement Agreement compliance infrastructure and wholesale contracts. In FY2025, two premier wholesale distributors accounted for 23% and 19% of consolidated net revenues, respectively. Stringent FDA marketing restrictions and retail display contracts create prohibitive barriers to entry for potential new combustible cigarette competitors.
A favorable cycle scenario entails recovering consumer discretionary purchasing power, moderating combustible cigarette volume contraction toward low-single-digit rates annually, and strict FDA enforcement against illicit disposable vapes that redirects volume back into authorized combustible brands and modern nicotine pouches. Under these conditions, premium brand equity remains fully intact, price realization easily compensates for volume decline, and modern oral pouch platforms experience rapid adoption across nationwide convenience and grocery store networks.
Reduce. Altria's near-term dividend yield (~5.9%) and robust free cash flow ($9.07B in FY2025) are overextended at $75.11, trading 21.9% above mid fair value ($61.61). Compounding cigarette volume losses (-4.5% trade-adjusted in Q2 2026), discount category expansion to 33.8%, and smoke-free execution roadblocks leave the stock vulnerable to terminal multiple de-rating.345
Altria Group, Inc. is a leading U.S. consumer defensive manufacturer specializing in combustible tobacco and smoke-free nicotine products for adult consumers aged 21 and older. Its wholly owned operating companies include Philip Morris USA Inc. (PM USA), the manufacturer of Marlboro cigarettes; John Middleton Co., a leading domestic machine-made cigar manufacturer; U.S. Smokeless Tobacco Company LLC (USSTC), the leading producer of moist smokeless tobacco including Copenhagen and Skoal; Helix Innovations LLC, manufacturer of on! oral nicotine pouches; and NJOY, LLC, an e-vapor manufacturer with marketing granted orders from the FDA. Altria also holds a majority-owned joint venture, Horizon Innovations LLC, for heated tobacco products, as well as significant equity investments in Anheuser-Busch InBev SA/NV (ABI) and Cronos Group Inc..
The company reports through two primary operating segments: Smokeable Products and Oral Tobacco Products, alongside an All Other category that includes NJOY and novel platforms. In FY2025, Smokeable Products generated $20,485M in net revenues and $10,984M in operating companies income, while Oral Tobacco delivered $2,802M in revenues and $1,828M in operating income. Sales are concentrated domestically, with two wholesale distributors accounting for 23% and 19% of consolidated net revenues in FY2025, respectively.
A stress test combining combustible volume contraction beyond 8.0% YoY, discount cigarette market share expansion above 35%, and multiple de-rating to 9.0x forward earnings severely challenges Altria's capital structure and shareholder return model. Altria carries $24,577M in total debt and negative stockholders' equity of -$2,668M as of June 30, 2026 following years of debt-funded share repurchases and progressive dividends. While Altria generated $9,290M in operating cash flow and $9,074M in free cash flow in FY2025, dividend commitments require ~$7.2B annualized ($3.6B paid in H1 2026). Historically, management retains only ~$1.0B in excess cash flow after dividends. A 15-20% contraction in Smokeable segment operating income ($10,984M in FY2025) would eliminate discretionary free cash flow, halt share repurchases ($335M in H1 2026), and strain investment in smoke-free manufacturing platforms ($375M-$450M guided 2026 CapEx). Under higher refinancing rates on its $24.58B debt load, interest coverage would deteriorate rapidly.
In Q2 2026, reported domestic cigarette shipment volume declined 3.2% (4.5% adjusted for trade inventories) with Marlboro down 7.4%. If the FDA finalizes product standards banning menthol in cigarettes, Altria's combustible volume losses would accelerate beyond 8% YoY, eliminating the ability of pricing realization to offset volume loss and impairing smokeable operating income ($10,984M in FY2025), inducing an estimated -24.5% fair value shock.47
투자 논리를 약화시킬 수 있는 다섯 가지 변화입니다.
Accelerating combustible volume losses would overwhelm annual price realization (~7% Marlboro price increases), causing Smokeable segment operating income ($10,984M in FY2025) to contract in absolute dollars.
현재:-3.2% reported (-4.5% trade-adjusted) YoY in Q2 2026
다음이면 경고Sustained domestic cigarette volume contraction exceeding -6.0% YoY
Altria's wide economic moat is anchored by Marlboro, an iconic American consumer brand that has dominated U.S. combustible tobacco for over four decades. In Q2 2026, Marlboro accounted for 59.6% of the domestic premium cigarette category and 39.5% of total cigarette retail sales. This entrenched brand equity confers extraordinary pricing power, allowing PM USA to implement compounding ~7% annual retail price increases. Because adult cigarette demand exhibits inelastic behavior with a stable -0.35 elasticity coefficient, pricing realization has systematically outpaced volume declines, sustaining Smokeable operating companies income of $10,984M in FY2025 and generating H1 2026 adjusted OCI margins of 64.9%.
Beyond brand equity, Altria is protected by formidable regulatory barriers to entry. Strict marketing bans under the Master Settlement Agreement and comprehensive FDA regulatory oversight prevent new entrants from advertising or scaling competing combustible products. Altria's commercial scale leverages deeply integrated wholesale and retail partnerships, with two core wholesale distributors accounting for 23% and 19% of consolidated net revenue in FY2025. This route-to-market advantage provides retail shelf placement that competitors cannot replicate, enabling the distribution of on! PLUS across 120,000 stores nationwide.
Nevertheless, the moat's durability is narrowing due to secular shifts in nicotine consumption. Combustible volume is declining at 4-5% annually as consumers migrate toward modern oral pouches and e-vapor products. In these transition categories, Altria lacks pricing dominance. Helix's on! captured only 14.4% of pouch volume in Q2 2026, and NJOY ACE remains absent from the marketplace following ITC exclusion orders. Consequently, while current economic profits remain massive, the long-term terminal durability of Altria's moat faces structural degradation.
Altria extracts substantial economic profits from its core tobacco franchises. Consolidated operating income reached $9,899M on $23,279M of net revenues in FY2025, generating an operating margin of 42.52%. Because capital expenditures were only $216M in FY2025 and reinvestment requirements track at ~2.0% of NOPAT, returns on tangible invested capital vastly exceed the company's computed WACC of 6.97% and moderate cost of equity of 7.46%. However, reported stockholders' equity is negative (-$2,668M as of June 30, 2026) due to extensive debt-funded capital distributions, so economic profit durability depends entirely on sustaining smokeable pricing realization against volume declines.26
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward path, then discount that future share value back to the analysis date.
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($61.61). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $7.6B after modeled reinvestment of $155.6M, with terminal value at 78.8% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
The Base scenario reflects the modal operating path: combustible volume secular decline is successfully mitigated by disciplined, continuous price realization. Marlboro maintains premium dominance while discount brands like Basic capture trade-down smokers. Smoke-free progress is modest, with on! growing absolute volume but losing pouch category share to dominant competitors, and NJOY remaining sidelined. Operating cash flow remains robust around $9.0B-$9.5B, enabling steady dividend payments ($4.44 per share) and modest share buybacks. However, with market price ($75.11) exceeding mid fair value ($61.61), investor returns are constrained.
A single-quarter earnings beat driven by pricing realization or timing benefits on cigarette import and export credits does not resolve multi-year combustible volume contraction (-4.5% trade-adjusted in Q2 2026) or justify the current 21.9% valuation premium over mid fair value ($61.61).
Results matching consensus confirm the mature, slow-growth cash extraction trajectory modeled in our baseline forecast (revenue growth of 0.5% to 1.2% and EPS of $5.68 in FY2026), leaving current market prices ($75.11) substantially overextended relative to intrinsic value.
A quarterly earnings miss would signal an elasticity break in Marlboro pricing power or accelerated discount trade-down by adult smokers, impairing smokeable operating income and pushing equity value below Fair value.
Altria exhibits clean underlying cash flow conversion but significant divergence between GAAP and non-GAAP earnings due to recurring special items. In FY2025, reported GAAP diluted EPS was $4.12 while adjusted diluted EPS was $5.42, reflecting $1,921M in after-tax asset impairment charges ($0.53/share non-cash goodwill impairment in e-vapor) and $110M in intangible amortization. In H1 2026, reported diluted EPS rose 30.9% to $2.67 while adjusted diluted EPS grew 4.9% to $2.80, reconciling across $94M in pre-tax restructuring costs for the USSTC facility consolidation, $97M in litigation charges, and $78M in ABI-related losses. Operating cash flow of $9,290M in FY2025 easily covered reported net income of $6,947M, confirming high core cash conversion despite portfolio write-downs.6
Consensus earnings estimates have demonstrated exceptional stability following Q2 2026 results. Full-year FY2026 consensus diluted EPS is $5.68, aligning squarely within management's narrowed guidance range of $5.61 to $5.72. FY2027 EPS consensus stands at $5.86 on revenue of $20,717M. Material post-earnings revisions have recorded 0% change across major consensus trackers, reflecting broad agreement on Altria's steady cash extraction profile.14
Determines whether ongoing retail price hikes can continue without breaking brand equity and triggering premium volume erosion.
Monitors adult smoker discretionary income strain and consumer trade-down, which dilutes consolidated margin mix.
Cash flow generation remains Altria's primary investment attribute. Operating cash flow reached $9,290M in FY2025, delivering free cash flow of $9,074M after deducting $216M of CapEx. Cash conversion from FY2025 operating income ($9,899M) was 93.8%, demonstrating minimal working capital drag and negligible capital intensity. However, cash flow stability is highly reliant on two wholesale customers who generated 42% of FY2025 net revenue (23% and 19%). As long as combustible pricing realization (~7% Marlboro price increases) offsets volume drops (-4.5% adjusted in Q2 2026), cash flow remains steady, but cushion beyond dividend payments is narrow.4
Altria operates with negative reported stockholders' equity (-$2,668M as of June 30, 2026; -$3,502M at year-end 2025) resulting from cumulative debt-funded share repurchases and regular dividend payouts exceeding historical retained earnings. Consequently, traditional accounting ROE is not meaningful. When measured against tangible invested capital, Altria's return on capital is high, driven by smokeable adjusted OCI margins of 64.9% in H1 2026. However, economic rent generation is in structural decline as combustible volume falls 4-5% annually and modern smoke-free platforms dilute enterprise margin mix.
Tangible return on invested capital significantly exceeds Altria's computed WACC of 6.97%, generating vast positive economic spread today. However, terminal value growth is constrained to 1.5% due to secular combustible volume contraction.
In FY2025, Smokeable Products delivered $10,984M of operating income on $20,485M , while Oral Tobacco generated $1,828M OCI on $2,802M revenue, and All Other produced an operating loss of -$229M.
| 매출 | US$23,279,000,000 |
|---|---|
| 매출원가 | US$8,737,000,000 |
| 매출총이익 | US$14,542,000,000 |
| 영업비용 | US$4,643,000,000 |
| 영업이익 | US$9,899,000,000 |
| 영업외 항목 및 세금 | -US$2,952,000,000 |
| 순이익 | US$6,947,000,000 |
| 총자산 | US$35,017,000,000 |
|---|---|
| 현금 | US$4,474,000,000 |
| 유동자산 | US$5,932,000,000 |
| 총부채 | US$38,469,000,000 |
| 유동부채 | US$9,154,000,000 |
| 자본잠식 | US$3,452,000,000 |
| 순이익 | US$6,947,000,000 |
|---|---|
| 영업 현금 유입 | US$9,290,000,000 |
| 감가상각비 | US$266,000,000 |
| 기타 영업 조정 | US$2,077,000,000 |
| 영업 현금흐름 | US$9,290,000,000 |
| 사용 가능 현금 | US$12,448,000,000 |
| 기초 현금 | US$3,158,000,000 |
| 투자 현금 유출 | US$341,000,000 |
| 자본적 지출 | US$216,000,000 |
| 기타 투자 활동 | US$125,000,000 |
| 재무 현금 유출 | US$7,615,000,000 |
| 순부채 발행 | US$385,000,000 |
| 자사주 매입 | US$1,000,000,000 |
| 지급 배당금 | US$6,960,000,000 |
| 기타 재무 활동 | US$40,000,000 |
| 기말 현금 | US$4,492,000,000 |
| 투자 현금흐름 | -US$341,000,000 |
| 재무 현금흐름 | -US$7,615,000,000 |
출처: SEC EDGAR · 제출일 2026-02-25 · SEC EDGAR
| 영업 부문별 매출 | 매출 | 비중 | 전년 대비 |
|---|---|---|---|
| Smokeable Products | US$204.9억 | 88% | -3.4% |
| Oral Tobacco | US$28억 | 12% | 0.9% |
| All Other Segments | US$500만 | 0% | — |
2026-10-18 분석에 사용된 시점 재무 데이터입니다.
| 기간 | 매출 | EBITDA | 순이익 | 영업 현금흐름 | 잉여 현금흐름 | 자본적 지출 | 감가상각비 | 주식 기반 보상 | 자사주 매입 | 지급 배당금 | 순부채 발행 | 투자 현금흐름 | 재무 현금흐름 | 기초 현금 | 기말 현금 | 현금 및 투자자산 | 총부채 | 영업이익률 | ROIC | WACC | ROIC−WACC 스프레드 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | US$257.4억 | US$228.1억 | US$142.4억 | US$38.3억 | US$36.4억 | US$1.9억 | US$2억 | US$4400만 | US$10.3억 | US$45.1억 | — | US$37.1억 | -US$53.3억 | — | US$46.5억 | US$45.7억 | US$138.8억 | 34.0% | — | 4.9% | — |
| 2017-12-31 | US$255.8억 | US$107.7억 | US$102.2억 | US$49억 | US$47억 | US$2억 | US$2.1억 | US$5500만 | US$29.2억 | US$48.1억 | — | -US$4.7억 | -US$77.7억 | US$46.5억 | US$13.1억 | US$12.8억 | US$138.9억 | 37.5% | — | 5.1% | — |
| 2018-12-31 | US$253.6억 | US$102.6억 | US$69.6억 | US$83.9억 | US$81.5억 | US$2.4억 | US$2.3억 | US$4600만 | US$16.7억 | US$54.2억 | — | -US$129.9억 | US$47.2억 | US$13.1억 | US$14.3억 | US$13.9억 | US$130.4억 | 35.9% | — | 5.4% | — |
| 2019-12-31 | US$251.1억 | US$23.2억 | -US$12.9억 | US$78.4억 | US$75.9억 | US$2.5억 | US$2.3억 | US$87억 | US$8.5억 | US$60.7억 | — | -US$24억 | -US$47.1억 | US$14.3억 | US$21.6억 | US$21.2억 | US$280.4억 | 41.1% | — | 3.7% | — |
| 2020-12-31 | US$261.5억 | US$83.8억 | US$44.7억 | US$83.9억 | US$81.5억 | US$2.3억 | US$2.6억 | US$28.6억 | US$0 | US$62.9억 | — | -US$1.4억 | -US$54억 | US$21.6억 | US$50.1억 | US$244.7억 | US$294.7억 | 41.6% | — | 3.0% | — |
| 2021-12-31 | US$260.1억 | US$52.6억 | US$24.8억 | US$84.1억 | US$82.4억 | US$1.7억 | US$2.4억 | US$67.2억 | US$16.8억 | US$64.5억 | — | US$12.1억 | -US$100.3억 | US$50.1억 | US$45.9억 | US$180.3억 | US$280.4억 | 44.4% | — | 3.8% | — |
| 2022-12-31 | US$251억 | US$87.4억 | US$57.6억 | US$82.6억 | US$80.5억 | US$2.1억 | US$2.3억 | US$5000만 | US$18.3억 | US$66억 | -US$11.1억 | US$7.8억 | -US$95.4억 | US$45.9억 | US$40.9억 | US$40.3억 | US$266.8억 | 47.5% | — | 6.1% | — |
| 2023-12-31 | US$244.8억 | US$123.2억 | US$81.3억 | US$92.9억 | US$90.9억 | US$2억 | US$2.7억 | US$5800만 | US$10억 | US$67.8억 | -US$5.7억 | -US$12.8억 | -US$83.7억 | US$40.9억 | US$37.2억 | US$36.8억 | US$262.3억 | 47.2% | — | 5.9% | — |
| 2024-12-31 | US$240.2억 | US$150.7억 | US$112.6억 | US$87.5억 | US$86.1억 | US$1.4억 | US$2.9억 | — | US$34억 | US$68.5억 | -US$11.2억 | US$21.8억 | -US$114.9억 | US$37.2억 | US$31.6억 | US$31.3억 | US$249.3억 | 46.8% | — | 6.9% | — |
| 2025-12-31 | US$232.8억 | US$108.3억 | US$69.5억 | US$92.9억 | US$90.7억 | US$2.2억 | US$2.7억 | — | US$10억 | US$69.6억 | US$3.9억 | -US$3.4억 | -US$76.2억 | US$31.6억 | US$44.9억 | US$44.7억 | US$257.1억 | 42.5% | — | 6.1% | — |
Altria Group Inc. (MO) trades at 11.9x forward earnings against a peer median of 15.2x. Its EV/EBITDA of 9.4x compares with a peer median of 10.7x. The comparison uses 4 peers: Target Corporation, Kimberly-Clark Corporation, Philip Morris International Inc. and Constellation Brands Inc., as of 2026-10-18.
The domestic tobacco industry operates in an advanced capital contraction phase characterized by negligible capital expenditures and zero physical capacity additions. Industry capex-to-revenue stands at -0.9% and industry capex-to-depreciation tracks at 0.71x. Altria expended only $216M on CapEx in FY2025 against $9,290M in operating cash flow and $23,279M in net revenues. Even with 2026 CapEx guided upward to $375M-$450M to fund the USSTC manufacturing facility consolidation, enterprise reinvestment remains exceptionally modest at ~2.0% of NOPAT.6
A favorable cycle scenario entails recovering consumer discretionary purchasing power, moderating combustible cigarette volume contraction toward -2.0% to -2.5% annually, and strict FDA enforcement against illicit disposable vapes that redirects volume back into authorized combustible brands and modern nicotine pouches. Under these conditions, premium brand equity remains fully intact, price realization easily compensates for volume decline, and modern oral pouch platforms experience rapid adoption across nationwide convenience and grocery store networks.
An adverse cycle scenario is characterized by persistent consumer inflation, elevated living expenses, and depressed discretionary spending among adult nicotine consumers. This dynamic accelerates consumer trade-down from premium cigarettes into discount offerings, pushing industry discount share above 35%, while combustible volume declines accelerate beyond -5.0% trade-adjusted. Concurrently, weak regulatory enforcement allows unauthorized, illicit disposable e-vapor products to flood retail channels, displacing legal combustible and modern oral nicotine consumption.
Altria occupies the dominant profit pool in the U.S. tobacco industry, capturing $10,984M in Smokeable segment operating income in FY2025 and generating an adjusted operating margin of 64.9% in H1 2026. However, its pure domestic focus leaves it 100% exposed to U.S. regulatory scrutiny and secular cigarette contraction, unlike global peer Philip Morris International (PM), which generates 10.4% revenue growth and commands a $319.8B market cap. Altria's positioning is defensive, highly cash-generative, but fundamentally mature and transitioning slowly.7
0-2% (Underweight). In accordance with our house Reduce rating and a 21.9% price premium to mid fair value ($61.61), overall portfolio exposure should be kept underweight (0-2%). Existing holders should trim into market strength, while income investors dependent on dividend cash flow should restrict holding size to an underweight posture with strict downside stops.
Risk management centers on capital preservation given the company's negative stockholders' equity and substantial total debt load. Investors must avoid averaging down above Fair value ($61.61) and enforce disciplined stops against sudden regulatory actions or volume contraction shocks.
Trading at an 11.89x forward P/E and a 21.9% premium to mid fair value ($61.61), the total return outlook is negative (-18.0% implied return), outweighing the ~5.9% dividend yield. Capital preservation demands avoiding new commitments.3
For income-mandated investors holding low-basis positions, the dividend ($4.44 per share annualized) is supported by $9.07B in free cash flow. However, holdings should be capped at underweight levels.5
With $24.58B in total debt, negative equity of -$2.67B, 42% revenue concentration in two distributors, and ongoing FDA menthol risk, risk-adjusted returns are unfavorable.37
We issue a Reduce recommendation on Altria Group Inc. (MO). Trading at $75.11 as of October 16, 2026, the stock trades at a 21.9% premium to mid intrinsic fair value of $61.61 (implied return of -18.0%). While Altria continues to extract robust free cash flow ($9,074M in FY2025) to support its ~5.9% dividend yield, the current valuation provides zero buffer against compounding combustible volume declines (-4.5% trade-adjusted in Q2 2026), discount trade-down to 33.8%, and smoke-free execution delays.345
Investors should capitalize on share price strength to reduce equity exposure toward an underweight posture. Capital is better deployed into defensive consumer assets where cash flow growth is supported by unit volume stability rather than pure pricing extraction in contracting categories.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
In the Bear scenario, persistent macro inflation breaks Marlboro's pricing elasticity, forcing management to escalate promotional discounting to stem market share loss. An accelerated regulatory ban on menthol or flavor restrictions destroys significant combustible profit pools. Meanwhile, smoke-free diversification fails to achieve required scale, leaving the company vulnerable to terminal multiple de-rating. Operating cash flow declines, tightening coverage of the dividend and forcing a cessation of share repurchases, driving equity valuation down toward the $44.36 lower bound.
In Q2 2026, discount cigarette industry share jumped 2.6 percentage points to 33.8% as adult consumers faced persistent inflation and strained discretionary income. If ongoing 7% annual Marlboro price hikes trigger an elasticity break, forcing Altria to expand promotional allowances to protect market share, consolidated operating margin would fall below 39.5% from 42.52% reported in FY2025, resulting in an estimated -18.2% fair value impact.46
Altria's current forward P/E is 11.89x. With NJOY ACE barred from importation in 2026, on! pouch share falling 1.7 pp to 14.4% in the pouch category, and illicit vapes continuing to displace combustible volume, the equity market would re-rate Altria as a structurally contracting melting pot, compressing its terminal P/E multiple by 20% to 9.0x or below, inflicting a -20.0% fair value impact.347
The base valuation assumes computed moderate Ke of 7.46%, which incorporates a low raw beta of 0.4381. Normalizing beta to the sector average levered beta of 0.7943 pushes normalized Ke to 8.44%. If higher benchmark rates and debt refinancing costs on $24.58B in total debt push discount rates 200 bps above moderate Ke (crossing the 9.46% danger threshold), equity fair value declines by -22.8%.23
Share losses in Altria's flagship premium brand indicate that cumulative pricing hikes are eroding brand equity, forcing promotional discounting that compresses operating margins.
현재:39.5% in Q2 2026 (down 1.5 percentage points YoY from 41.0% in Q2 2025)
다음이면 경고Marlboro total retail category share falling below 38.0%
Consumer trade-down driven by cumulative inflation pressures adult smokers to abandon premium Marlboro, forcing Altria to expand margin-dilutive promotional allowances.
현재:33.8% of cigarette industry in Q2 2026 (up 2.6 percentage points YoY)
다음이면 경고Discount category industry retail share crossing 36.0%
Failure of on! and on! PLUS to defend pouch market share against dominant competitors leaves Altria without a growing profit engine to offset declining traditional moist smokeless tobacco ($1,828M FY2025 OCI) and cigarettes.
현재:14.4% in Q2 2026 (down 1.7 percentage points YoY)
다음이면 경고on! share of modern oral nicotine pouch category falling below 12.0%
Extreme wholesale concentration exposes Altria's route-to-market and finished goods cash collections to systemic counterparty risk across smokeable, oral, and e-vapor segments.
현재:42.0% of consolidated net revenues from top two wholesale distributors in FY2025 (23% and 19%)
다음이면 경고Operational disruption, credit distress, or distribution fee renegotiation by either top distributor
| medium |
| 12 to 24 months |
| Deploying a tiered portfolio approach, introducing Marlboro Cowboy Cut to retain value-sensitive premium smokers and leveraging Basic in discount. |
| FDA implementation of product standards banning menthol in combustible cigarettes and restricting pouch flavors | high | 12 to 36 months | Engaging in scientific advocacy, preparing non-menthol alternative product portfolios, and pursuing PMTA authorizations for modified-risk alternatives. |
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Discounted forecast-period cash flows (US$19.51) plus discounted terminal value (US$72.32) minus signed per current share (US$12.72) equals the US$79.12 lens value shown above. Negative net debt is , so subtracting it raises value.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Solve for the growth rate that makes the model value equal the report-date share price.
In the Bull scenario, adult consumer discretionary income recovers, curtailing discount trade-down. Regulatory enforcement against illicit disposable vapes redirects nicotine volume back into Marlboro and authorized oral nicotine pouches. Helix's national rollout of on! PLUS across 120,000 stores scales rapidly, turning the smoke-free segment into an accretive profit driver. Altria's FCF generation comfortably supports annual dividend increases and >$1B in annual share repurchases, justifying valuation near the top of the fair value range ($84.57).
Measures the commercial scaling and competitive viability of Altria's primary smoke-free growth vehicle against category leaders.
Essential for determining whether Altria can participate in the largest reduced-risk nicotine category or face further asset write-downs.
Represents extreme counterparty and working capital concentration risk across nationwide wholesale routes to market.
| $23.98B |
| $24.13B |
| $24.25B |
| Revenue growth | 1.2% | 1.0% | 0.8% | 0.6% | 0.5% |
| Operating margin | 42.6% | 42.8% | 43.0% | 43.1% | 43.2% |
| Operating income | $10.04B | $10.18B | $10.31B | $10.40B | $10.48B |
| Tax rate | 22.5% | 22.5% | 22.5% | 22.5% | 22.5% |
| NOPAT | $7.78B | $7.89B | $7.99B | $8.06B | $8.12B |
| Reinvestment | $155.56M | $157.85M | $159.86M | $161.19M | $162.37M |
| Reinvestment rate (of NOPAT) | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% |
| Free cash flow to firm | $7.62B | $7.73B | $7.83B | $7.90B | $7.96B |
| Smokeable Products revenue | $20.73B | $20.94B | $21.11B | $21.23B | $21.34B |
| Oral Tobacco revenue | $2.84B | $2.86B | $2.89B | $2.91B | $2.92B |
| All Other Segments revenue | $4.71M | $4.76M | $4.80M | $4.83M | $4.85M |
| Terminal growth | 1.5% | 1.5% | 1.5% | 1.5% | 1.5% |
Altria's capital allocation framework prioritizes cash returns to shareholders, anchored by a progressive dividend commitment targeting an ~80% adjusted EPS payout ratio. In H1 2026, Altria returned $3.9B to shareholders, comprising $3.6B in cash dividends and $335M in share repurchases (5.3M shares repurchased at an average price of $62.78). The company had $665M remaining under its $2.0B share repurchase authorization as of June 30, 2026. Capital expenditures remain highly disciplined ($216M in FY2025; guided to $375M-$450M in 2026 to support USSTC facility consolidation). Post-dividend discretionary excess cash flow tracks at ~$1.0B annually, which is allocated between opportunistic buybacks and debt management across $24,577M in total debt. Altria also holds valuable liquid stakes in Anheuser-Busch InBev ($8,896M equity investment value at Q2 2026) and Cronos Group.
In FY2025, two wholesale distributors accounted for 23% and 19% of consolidated net revenues, respectively, with no other customer exceeding 10%.
Any counterparty insolvency, inventory de-stocking, or contractual dispute by either major distributor poses an immediate threat to quarterly shipments and working capital cash flow.
Altria recorded $903M in pre-tax impairment and exit charges in H1 2025, including an $873M goodwill impairment on e-vapor, followed by NJOY ACE being barred from importation in 2026.
M&A execution in reduced-risk alternatives has destroyed substantial balance-sheet equity, slowing smoke-free diversification and forcing reliance on internal on! pouch expansion.
| 마진 |
|---|
| MO | Altria Group Inc. | $125.4B | 11.9x | 6.1x | 9.4x | — | — |
| TGT | Target Corporation | $70.1B | 16.2x | 0.7x | 9.8x | 26.4% | 6.0% |
| KMB | Kimberly-Clark Corporation | $35.0B | 14.3x | 2.1x | 11.7x | 104.9% | 19.0% |
| PM | Philip Morris International Inc. | $319.8B | 22.3x | 7.5x | 20.3x | — | 40.0% |
| STZ | Constellation Brands Inc. | $22.2B | 10.9x | 2.4x | 9.6x | 24.0% | 33.6% |
| negative |
| The persistent availability of unauthorized, flavored disposable e-vapor products continues to capture adult nicotine consumers, siphoning volume away from authorized combustible and smoke-free products. |
| Re-evaluate Marlboro price elasticity durability and exit remaining equity exposure. |
| on! Category Share in Oral Nicotine Pouches | Category share falling below 12.5% (vs 14.4% in Q2 2026) | Remove smoke-free transition growth premium from valuation terminal multiple assumptions. |
| Wholesale Concentration & Days Sales Outstanding | DSO extending by >5 days or credit deterioration at top two distributors | Hedge distribution counterparty exposure and re-examine short-term receivables liquidity. |
The primary upside opportunity lies in Altria's commercial expansion of on! PLUS across 120,000 retail stores, which leverages existing retail distribution channels to convert adult smokers into smoke-free modern oral nicotine pouches and expand high-margin profit pools, supported by accelerated FDA enforcement against illicit disposable e-vapor products to stabilize category volume declines and drive terminal multiple expansion.
